Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for anterior ischemic optic neuropathy
IRCT20181109041596N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anterior ischemic optic neuropathy (AION) comparing Fluoxetine plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoints: Visual acuity and Visual evoked potential. Started Dec 2018; status: completed.
02
Drugs
fluoxetine
03
Conditions
anterior ischemic optic neuropathy (AION)
Beyond the preview
Go deeper on IRCT20181109041596N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181109041596N1.